Company news

Theravance Biopharma, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Theravance Biopharma, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

May 7, 2023

Theravance Biopharma to Report First Quarter 2023 Financial Results on May 8, 2023

April 23, 2023

Theravance Biopharma, Inc. Announces Appointment of Jim Kelly, Managing Director at Weiss Asset Management, to Board of Directors

April 10, 2023

Theravance Biopharma, Inc. Announces Strategic Actions and Reports Fourth Quarter / Full Year 2022 Financial Results and Business Update

February 26, 2023

Theravance Biopharma to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023

February 20, 2023

Theravance Biopharma, Inc. Highlights 2022 Accomplishments and 2023 Key Targets

January 8, 2023

Theravance Biopharma, Inc. Announces Final Results of Tender Offer

November 21, 2022

Theravance Biopharma, Inc. Announces Preliminary Results of Tender Offer

November 17, 2022

Theravance Biopharma, Inc. Reports Third Quarter 2022 Financial Results, Provides Business Update and Extends Tender Offer

November 6, 2022

Ampreloxetine Data in Neurogenic Orthostatic Hypotension to be Presented at the 33rd International Symposium on the Autonomic Nervous System

November 1, 2022

Theravance Biopharma to Report Third Quarter 2022 Financial Results on November 7, 2022

October 30, 2022

Theravance Biopharma to Present New Ampreloxetine Data in Neurogenic Orthostatic Hypotension at the 33rd International Symposium on the Autonomic Nervous System

October 24, 2022

Theravance Biopharma Announces Tender Offer For Up To $95 Million Of Its Ordinary Shares

September 27, 2022

Theravance Biopharma, Inc. Initiates $250 Million Capital Return Program

September 18, 2022

Theravance Biopharma to Present at Upcoming Investor Conferences

September 5, 2022

Theravance Biopharma, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

August 3, 2022

Theravance Biopharma to Report Second Quarter 2022 Financial Results on August 4, 2022

July 27, 2022

Theravance Biopharma Announces Tender Offer For Outstanding 3.25% Convertible Senior Notes Due 2023

July 25, 2022

Theravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma for Approximately $1.1 Billion in Upfront Cash with Over $1.5 Billion in Potential Total Value

July 12, 2022

Theravance Biopharma, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

May 4, 2022

Theravance Biopharma to Report First Quarter 2022 Financial Results on May 5, 2022

May 1, 2022

Theravance Biopharma, Inc. Announces Results from Study 0170, a Second Phase 3 Study of Ampreloxetine, in Patients with Symptomatic Neurogenic Orthostatic Hypotension (nOH)

April 3, 2022

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

February 22, 2022

Theravance Biopharma to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022

February 8, 2022

Theravance Biopharma, Inc. Announces Enrollment of First Patient in YUPELRI® Phase 4 Study

January 9, 2022

Theravance Biopharma to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 4, 2022

Theravance Biopharma, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update

November 2, 2021

Theravance Biopharma to Report Third Quarter 2021 Financial Results November 3, 2021

October 19, 2021

Theravance Biopharma, Inc. Announces Top-line Results from a Phase 3 Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension

September 14, 2021

Theravance Biopharma, Inc. Announces Strategic Actions to Focus on Respiratory Disease Portfolio

September 14, 2021

Theravance Biopharma, Inc. Announces Top-line Results from Phase 2b Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis

August 22, 2021

Theravance Biopharma, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update

August 2, 2021

Theravance Biopharma to Report Second Quarter 2021 Financial Results on August 3, 2021

July 19, 2021

Theravance Biopharma, Inc. Announces Proposed Public Offering of Ordinary Shares

June 23, 2021

Theravance Biopharma, Inc. Announces Pricing of Public Offering of Ordinary Shares

June 23, 2021

Theravance Biopharma, Inc. Announces Top-Line Results From Phase 2 Study of Nezulcitinib In Patients Hospitalized With Acute Lung Injury Due to COVID-19

June 20, 2021

Theravance Biopharma, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update

May 3, 2021

Theravance Biopharma to Report First Quarter 2021 Financial Results on May 4, 2021

April 19, 2021

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

February 22, 2021

Theravance Biopharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 23, 2021

February 8, 2021

Theravance Biopharma To Present at the 39th Annual J.P. Morgan Healthcare Conference

January 4, 2021

Theravance Biopharma to Present at the 3rd Annual Evercore ISI HEALTHCONx Conference

November 16, 2020

Theravance Biopharma, Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update

November 4, 2020

Theravance Biopharma to Report Third Quarter 2020 Financial Results on November 5, 2020

October 21, 2020

Theravance Biopharma, Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update

August 5, 2020

Theravance Biopharma to Report Second Quarter 2020 Financial Results on August 6, 2020

July 26, 2020

Theravance Biopharma Appoints Deepika R. Pakianathan, Ph.D. to Board of Directors

July 1, 2020

Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-0903 for the Treatment of Hospitalized Patients with Acute Lung Injury Caused by COVID-19

June 24, 2020

Theravance Biopharma, Inc. Reports First Quarter 2020 Financial Results and Provides Business Update

May 5, 2020

Theravance Biopharma to Report First Quarter 2020 Financial Results on May 6, 2020

April 27, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 20 calls. Every call is listed under its year.

Decks

The 5 newest of 80 decks. Every deck is listed under its year.